aap Implantate AG

Board/Management Information • Jun 15, 2017

News Details

Corporate | 15 June 2017 20:15

aap Implantate AG: Supervisory Board extends both Management Board members’ contracts prematurely until the end of 2020

DGAP-News: aap Implantate AG / Key word(s): Change of Personnel/Miscellaneous

15.06.2017 / 20:15

The issuer is solely responsible for the content of this announcement.

---

aap Implantate AG (“ aap “) announces that the Supervisory Board decided today to extend the contracts of Management Board Chairman Bruke Seyoum Alemu (CEO) and Chief Financial Officer Marek Hahn (CFO) prematurely for a further three years until the end of 2020.

Bruke Seyoum Alemu (52) has served aap in various top management positions for many years and has been the Chairman of the Management Board (CEO) since June 2014. He is responsible for Corporate Development, Research & Development, Production, Quality Assurance and Control, Regulatory Affairs as well as Sales and Marketing.

Marek Hahn (42) has been a member of the Management Board (CFO) at aap since April 2010. In his role as Chief Financial Officer he is responsible in the company for Finance/ Controlling, Human Resources, IT, Legal Affairs, Investor and Public Relations as well as Administration.

“By extending the contracts with Mr. Alemu and Mr. Hahn we focus on continuity at the top management level in the years ahead as well,” says Biense Visser, Chairman of the Supervisory Board at aap . “In recent years Mr. Alemu and Mr. Hahn have consistently and successfully undertaken the transformation of aap from a diversified medical technology company into a pure player in trauma. The company now has a comprehensive IP-protected product and technology portfolio as well as a strong liquidity position and can take even better advantage of the opportunities in the growing trauma market with its focused business model. Management Board and Supervisory Board must now continue to consequently implement the strategy in order to unlock the inherent value of our innovative product and technology base and thereby create sustainable value for aap’ s shareholders.”

_______________________________________________________________________________________

aap Implantate AG (ISIN DE0005066609) – Prime Standard/Regulated Market – All German stock markets –

About aap Implantate AG

aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven’t yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG’s stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company’s investor relations app from the Apple’s App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap ‘s public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

Contact:

aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 – 134; Fax.: ++49/30/750 19 – 290; f.franke@aap.de

---

15.06.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de

---

Language:	English
Company:	aap Implantate AG
	Lorenzweg 5
	12099 Berlin
	Germany
Phone:	+49 (0) 30 75 01 90
Fax:	+49 (0) 30 75 01 91 11
E-mail:	info@aap.de
Internet:	www.aap.de
ISIN:	DE0005066609
WKN:	506660
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

End of News	DGAP News Service